YOLFTbeta
Cisen Pharmaceutical Co Ltd

Cisen Pharmaceutical Co Ltd

603367 · SHG · Healthcare / Drug Manufacturers - Specialty & Generic

12.77CNY-0.21 (-1.62%)

Price History

Full chart

Market Stats

Previous Close12.98
Open13.01
Day Range12.70 – 13.04
52-Week Range12.13 – 24.85
Volume4.67M
Market Cap6.58B
P/E (TTM)14.53
Forward P/E0.00
EPS1.00
Dividend Yield2.97%
Beta0.15
50-Day Avg14.48
200-Day Avg15.60

About

Cisen Pharmaceutical Co., Ltd., together with its subsidiaries, research, develops, produces, and sells drug products. The company's chemical preparations include basic infusion, therapeutic infusion, liver disease medication, nervous system drugs, anti-tumor and adjuvant drugs, nutritional infusion, contrast agents, cardiovascular and cerebrovascular drugs, anti-infective drugs, anesthetic and analgesic drugs, obstetrics and gynecology medication, digestive system medication, respiratory system medication, immune system drugs, and hormonal drugs. It also offers Chinese medicine preparations; complete and incomplete nutritional formula food; specific nutritionally complete formula foods; nutritious food; health food; raw materials; and packaging products. The company was formerly known as Shandong Lukang Cisen Pharmaceutical Co., Ltd. and changed its name to Cisen Pharmaceutical Co., Ltd. in 2011. Cisen Pharmaceutical Co., Ltd. was founded in 1970 and is headquartered in Jining, the People's Republic of China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Zhenxin Du
  • Employees3.11K
  • HeadquartersTongji Science and Technology Industrial Park, Jining, China, China
  • Websitehttps://www.cisen-pharma.com

Leadership

  • Mr. Zhenxin DuGM & Chairman · b. 1967
  • Mr. Xinbing XuFinancial Director, Board Secretary, Accounting Supervisor & Director · b. 1978
  • Ms. Xiu Lian LuDeputy GM & Director · b. 1967
  • Mr. Liushan HaoDeputy GM & Director · b. 1970
  • Mr. Xianglin ZhangDeputy General Manager · b. 1970
  • Mr. Xiaoting CuiDeputy General Manager · b. 1979
  • Mr. Ze Lin RenDeputy General Manager · b. 1980

Financials

Income Statement

Currency: CNY2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.53B2.05B2.21B2.39B2.50B2.56B2.96B3.81B4.11B3.67B3.78B4.07B4.46B3.98B3.44B
Growth (%)-+33.98%+7.52%+8.27%+4.55%+2.72%+15.51%+28.54%+8.00%-10.66%+2.95%+7.49%+9.75%-10.77%-13.48%
Cost of Revenue920.70M1.24B1.42B1.54B1.61B1.52B1.49B1.68B1.79B1.61B1.73B1.83B1.91B1.81B1.66B
Gross Profit610.72M814.36M785.73M846.72M885.10M1.04B1.47B2.13B2.32B2.06B2.05B2.24B2.55B2.17B1.79B
Gross Margin39.88%39.69%35.62%35.45%35.45%40.74%49.71%55.99%56.43%56.17%54.32%55.06%57.14%54.46%51.89%
Operating Expense340.53M484.72M577.67M605.14M615.11M774.58M1.06B1.57B1.74B1.58B1.72B1.87B1.96B1.60B1.41B
Operating Income270.19M329.64M208.06M241.58M270.00M270.27M416.21M565.61M582.71M484.67M334.42M364.58M592.58M572.05M376.64M
Operating Margin17.64%16.07%9.43%10.11%10.81%10.54%14.05%14.85%14.17%13.19%8.84%8.97%13.28%14.37%10.93%
EBITDA279.54M349.52M236.35M430.55M469.30M482.33M572.87M678.17M629.75M517.92M432.08M519.77M781.54M683.33M698.69M
EBITDA Margin18.25%17.04%10.71%18.03%18.79%18.81%19.34%17.81%15.31%14.10%11.42%12.78%17.51%17.16%20.28%
Net Income236.93M283.86M208.30M220.15M246.85M246.88M367.22M503.54M514.58M438.78M334.15M349.96M521.34M508.91M421.25M
Net Income Margin15.47%13.84%9.44%9.22%9.89%9.63%12.40%13.22%12.51%11.94%8.83%8.61%11.68%12.78%12.23%
R&D61.09M97.52M123.98M135.03M103.89M108.69M142.00M325.98M310.56M309.58M334.35M335.17M374.88M345.94M285.78M
R&D as % of Total Revenue3.99%4.75%5.62%5.65%4.16%4.24%4.79%8.56%7.55%8.43%8.84%8.24%8.40%8.69%8.30%
Interest Expense0287.53K5.22M7.61M10.55M11.00M5.19M5.53M3.52M11.49M7.97M6.12M8.46M7.63M1.34M
Interest Expense % of Total Revenue0.00%0.01%0.24%0.32%0.42%0.43%0.18%0.15%0.09%0.31%0.21%0.15%0.19%0.19%0.04%

Balance Sheet

Currency: CNY2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.57B2.05B2.36B2.69B3.03B3.28B4.74B5.25B5.53B6.17B6.36B6.82B7.34B7.55B7.60B
Total Liabilities230.02M470.06M636.48M792.44M935.33M982.26M1.02B1.09B959.97M1.36B1.31B1.46B1.57B1.57B1.37B
Total Equity1.34B1.58B1.72B1.90B2.10B2.30B3.72B4.15B4.57B4.80B5.05B5.33B5.73B5.95B6.19B
Cash143.31M177.91M17.70M18.61M208.81M429.90M1.40B345.76M382.42M661.42M938.98M997.95M983.39M1.16B1.21B
Total Debt-100.00M100.00M150.00M150.00M250.00M154.00M129.25M100.00M330.00M143.63M158.61M167.34M80.57M-
Net Debt-143.31M-77.91M82.30M131.39M-58.81M-179.90M-1.25B-216.51M-282.42M-331.42M-795.34M-839.34M-812.71M-1.08B-

Cash Flow

Currency: CNY2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow76.28M33.09M81.26M27.54M266.24M291.97M439.61M406.68M181.26M431.01M233.60M258.35M451.24M570.85M466.37M
Investing Cash Flow-125.52M-64.02M-161.10M-25.03M-55.95M-84.28M-302.18M-1.38B-145.00M-47.03M327.48M-273.08M-378.13M-21.75M-
Financing Cash Flow124.12M56.05M-70.24M-1.60M-55.16M48.43M816.00M-69.06M-19.04M-83.96M-318.43M108.19M-133.80M-364.63M-
Capital Expenditure130.58M28.85M224.88M48.68M19.09M42.45M23.98M40.36M103.37M202.27M51.02M35.19M17.71M101.81M64.76M
Free Cash Flow-54.30M4.23M-143.62M-21.14M247.16M249.53M415.63M366.32M77.89M228.74M182.58M223.15M433.53M469.04M401.61M
Dividends Paid23.91M45.27M74.69M53.30M55.16M55.87M53.35M71.81M118.78M120.19M115.94M135.85M156.13M304.56M182.92M
FCF to OCF-71.18%12.80%-176.74%-76.78%92.83%85.46%94.55%90.08%42.97%53.07%78.16%86.38%96.08%82.17%86.11%
Dividend Paid to FCF-44.03%1069.11%-52.00%-252.06%22.32%22.39%12.84%19.60%152.49%52.54%63.50%60.88%36.01%64.93%45.55%

Earnings

Report DateOct 25, 2017Mar 28, 2018Apr 27, 2018Aug 22, 2018Oct 25, 2018Mar 20, 2019Apr 25, 2019Aug 15, 2019Oct 27, 2019Dec 31, 2019Apr 28, 2020Aug 11, 2020Oct 30, 2020Dec 31, 2020Apr 29, 2021Aug 19, 2021Oct 29, 2021Dec 31, 2021Apr 26, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023
EPS Estimate-----------------------
EPS Actual0.170.360.260.250.310.280.280.280.350.230.230.160.330.250.240.170.230.110.220.190.240.130.35
Surprise-----------------------
TimingAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hours-Pre-market-------Pre-market----

Key Statistics & Ratios

Market Cap6.58B
Enterprise Value2.94B
Trailing P/E14.53
Forward P/E0.00
Price / Sales1.94
Price / Book1.03
EPS1.00
Book Value14.10
Revenue (TTM)3.40B
Gross Profit (TTM)1.67B
EBITDA434.29M
Profit Margin13.44%
Operating Margin-0.88%
Return on Equity7.35%
Return on Assets1.83%
Shares Outstanding452.75M
Shares Float205.06M
Beta0.15
Dividend Yield2.97%
Dividend Rate0.43
Payout Ratio34.80%

Dividends

20231×
0.34Jun 14, 2023
20221×
0.30Jun 30, 2022
20211×
0.26Jun 25, 2021
20201×
0.27Jul 15, 2020
20191×
0.26May 23, 2019
20181×
0.16May 17, 2018